



CONTACT:
Equitilink LLC
Hanna Pajunen
877-788-1940
IR@nutrapharma.com

NUTRA PHARMA ANNOUNCES BOARD CHANGES AND LOAN SETTLEMENT

Boynton Beach, FL. – October 5, 2004 - Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced the settlement of a significant debt to one of its shareholders. Accordingly, the Board of Directors has been restructured as part of the Company's efforts to maintain focus on their core initiatives.

As reported in the Company's last quarterly report, on or about August 9, 2004, a Managing Member of Opus International, LLC made a formal demand for repayment of the loan made to the Company in the amount of \$1,384,931. On September 28, 2004, the Company entered into a settlement agreement with Opus International, LLC to satisfy the demand loan in its entirety.

Under the terms of the settlement, 6,000,000 common shares of Infected, Inc. were transferred to Opus International as payment in full for the outstanding debt. This transaction places a value on Infected of \$.23 per share. Infected (Pink Sheets: IFEC) was trading at a range of \$.09 - \$.10 during the negotiation of this settlement.

Infected currently has 15,537,030 common shares outstanding. The 6,000,000 shares in this transaction represent approximately 38.6% of Infected's outstanding common stock, and represents a change in control of Infected. Nutra Pharma retains approximately 4,529,570 shares of Infected, representing a 29.2% position and will seek to increase this position with further acquisition of Infected's outstanding stock.

Nutra Pharma's Chief Executive Officer, Rik Deitsch, will remain on the board of directors of Infected. Because of this divestiture, Nutra Pharma will no longer be responsible for the ongoing financing of Infected's business plan. This represents a cost-savings of the \$400,000 funding commitment to Infected as reported in the last quarter.

"This settlement effectively eliminates over ninety percent of Company debt, as well as eliminating the funding obligations that Nutra Pharma has made to Infected in the amount of \$400,000 over the next twelve months," commented Rik Deitsch, CEO of Nutra Pharma. "We will continue to help in the management of Infected and we consider them to be an important part of the Nutra Pharma family," he added.

The Company has also announced a restructuring of the Board of Directors and has accepted the resignations of Dr. Mitchell Felder, David C. McClelland and Dr. Soram Singh Khalsa. Stanley J Chelstein has accepted a position on the Board effective September 28, 2004.

Stanley J Chelstein is currently the CEO and President of Waiora, a company that develops and distributes Healthy Aging products. Mr. Chelstein was the past President and Chief Operating Officer of Unicity, Inc., a \$300 million nutritional supplement company with offices in thirteen

countries in North America, Asia and Europe. Prior to serving as President, he was the Chief Operating Officer of Unicity where he was responsible for global operations including supply chain, distribution, information technology, customer service, human resources and finance. From May 1999 to June 2002 Mr. Chernelstein served as the Senior Vice President of Finance and Operations at Rexall Showcase International (RSI), a division of Rexall Sundown. RSI was a \$180 million nutritional supplement company that operated in the USA, Japan, Korea, Taiwan and Hong Kong. Mr. Chernelstein began his career in public accounting at the firm of Cooper's and Lybrand where he worked for a total of five years including three years in auditing and two years in management consulting. After public accounting he worked as a Corporate Controller for six years in the wholesale distribution and retail industries. Mr. Chernelstein is a graduate of the University of Pittsburgh where he obtained a B.S. in Business and Accounting.

"I am very excited to be part of Nutra Pharma," remarked Stanley J Chernelstein. "This is a great time for the Company and I hope to be able to make a strong, positive contribution as Nutra Pharma grows into the future," he concluded.

"Stan's background in accounting, sales and marketing adds necessary experience to the Board that will allow Nutra Pharma to move from its development stage into near-term revenues," added Rik Deitsch.

About Nutra Pharma Corp.

The Company's minority-owned subsidiary, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's other holding Infected, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.nutrapharma.com>

About Infected, Inc.

Infected, Inc., is a biotechnology/genomics company that specializes in the research, development and production of laboratory kits used in the rapid identification and antibiotic sensitivity testing of disease-causing pathogens. The company's patents span the identification and antibiotic sensitivity testing of a family of disease-causing bacteria that includes: Tuberculosis, Para-tuberculosis, Pseudomonas, M. avium and Nocardia. These bacteria are cited as a prominent cause of death in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Infected's other patents include technology designed for use in the bioremediation of contaminated soil and water. Additionally, Infected also owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy.

<http://www.infected.com>

Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission. Nothing in this press release shall be construed as an offer to buy or sell any securities herein.

###